iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new brand for its core technology in 2019, the FastPharming System, which uses plants for the rapid and safe production of high-quality protein products.
“iBio began the journey to become a contract development and manufacturing organization (CDMO) in 2016 with the acquisition of a 130,000 square foot manufacturing facility in Texas, which was suitable for the plant-based production of clinical-grade biological medicines,” Tom Isett, strategic advisor and board member, says in an interview with BioTuesdays.
“Now the company is creating the commercial engine to take the FastPharming platform to market so that clients can quickly and easily produce high-quality therapeutics, vaccines and other products while speeding their ‘time-to-clinic.’”
“We’re also developing our own proprietary therapeutic pipeline using the system, as well as materials used for 3D bioprinting of tissue and organs,” he adds.
|
|
